- ►prsjournal.com MW Stewart, PJ Rosenfeld - British Journal of Ophthalmology, 2008 - bjo.bmj.com Vascular endothelial growth factor (VEGF), a potent vasoactive cytokine,
mediates the pathological angiogenesis and hyperpermeability associated with
several chorioretinal vascular disorders including neovascular age-related ... Cited by 9 - Related articles - BL Direct - All 5 versions
MW Stewart, PJ Rosenfeld - bjo.bmj.com Page 1. doi: 10.1136/bjo.2007.134874 2008 92: 667-668 originally published online
March 20, 2008 Br J Ophthalmol MW Stewart and PJ Rosenfeld ... Related articles - All 2 versions
[CITATION] A Randomized Dose-Escalation Trial of Locally-Administered Sirolimus to Treat Diabetic …
MS Blumenkranz, PU Dugel, WA Solley… - 2008 Annual Meeting of the Association of Reseach in …, 2008 Cited by 2 - Related articles
DV Do, QD Nguyen, SM Shah, DJ Browning, JA … - British Journal of Ophthalmology, 2009 - bjo.bmj.com Results: Injections of VEGF Trap-Eye were well tolerated with no ocular
toxicity. One patient had an unrelated serious adverse event: hospitalisation
for cellulitis of the left foot 27 days after injection of VEGF Trap-Eye. ... Cited by 4 - Related articles - All 4 versions
- ►jovr.ir [PDF] M Homayouni - Journal of Ophthalmic & Vision Research, 2009 - jovr.ir The introduction of pharmacotherapy has been one of the most important advances
in the management of retinal disorders. Age-related macular degeneration (AMD)
was once considered as an irrepressible disease leading to permanent ... Related articles - View as HTML - All 7 versions
K Csaky, DV Do - American Journal of Ophthalmology, 2009 - Elsevier Several prospective, randomized clinical trials have demonstrated that
intravitreal anti-VEGF therapies generally are well tolerated. However, within
these trials, there is some circumstantial evidence that links systemic ... Related articles - All 2 versions
RN Khurana, DV Do, QD Nguyen - International Ophthalmology Clinics, 2009 - journals.lww.com Diabetic retinopathy is the leading cause of blindness in people of working
age.1 Diabetic macular edema (DME) is the most common cause of moderate vision
loss among this population.2,3 The Early Treatment Diabetic Retinopathy ... Related articles - All 2 versions
Q Mohamed, TY Wong - Expert Opinion on Emerging Drugs, 2008 - Informa Pharma Science Diabetic retinopathy (DR) is prevalent even among “well controlled”
diabetics, and remains the commonest cause of visual loss in working age adults.
Current evidence based treatments, including intensive glycemic and ... Related articles - All 6 versions
PA Quiram, Y Song - la-press.com This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://www.creativecommons.org/licenses/by/2.0)
which permits unrestricted use, distribution and reproduction provided the ... Related articles - View as HTML - All 2 versions
PK KAISER - Retina, 2009 - journals.lww.com Clinical trials increasingly support the premise that inhibition of vascular
endothelial growth factor is a viable but insufficient target for long-term
control of age-related macular degeneration (AMD). Additional biologic ... Related articles - All 3 versions
